Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
Aptose Biosciences Inc. | Senior VP, CFO, and CBO | Employee Stock Option | 600K | Jan 18, 2022 | Direct | ||
Ikena Oncology, Inc. | CFO & Head of Corp. Dev. | Stock Option (Right to Buy) | 181K | Feb 1, 2024 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
IKNA | Ikena Oncology, Inc. | Feb 1, 2024 | 1 | $0 | 4 | Feb 2, 2024 | CFO & Head of Corp. Dev. |
IKNA | Ikena Oncology, Inc. | Jan 3, 2023 | 1 | $0 | 4 | Jan 5, 2023 | CFO & Head of Corp. Dev. |
IKNA | Ikena Oncology, Inc. | Apr 25, 2022 | 1 | $0 | 4 | Apr 25, 2022 | CFO & Head of Corp. Dev. |
IKNA | Ikena Oncology, Inc. | Apr 25, 2022 | 0 | $0 | 3 | Apr 25, 2022 | CFO & Head of Corp. Dev. |
APTO | Aptose Biosciences Inc. | Jan 18, 2022 | 1 | $0 | 4 | Jan 20, 2022 | Senior VP, CFO, and CBO |
APTO | Aptose Biosciences Inc. | Aug 19, 2021 | 2 | $0 | 4 | Aug 23, 2021 | Senior VP, CFO, and CBO |